Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

    If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation is provided for study participation time.

  • Study 1620: Male and Female Participants with Nasal Polyps

    Research Purpose: Study 1620 is designed to determine the safety and tolerability of an investigational drug being developed for the treatment of Chronic Rhinosinusitis with Nasal Polyps.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women may participate if they meet one of the following criteria: postmenopausal, hysterectomy and/or bilateral oophorectomy, medically confirmed ovarian failure, tubal ligation or bilateral salpingectomy.

    Age

    18-65 years

    Body Mass Index (BMI)

    Between 17.5 – 35.0 kg/m²

    Tobacco/Nicotine Use

    Must be willing to abstain from tobacco and/or nicotine containing products for 24 hours prior to dosing and during the clinic stay.

    Health History

    Must be healthy; with the exception of diagnosed nasal polyps and chronic rhinosinusitis.

    Restricted Medications

    All medications will be reviewed for inclusion prior to screening.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 12 months.

    Clinic Stay

    • Participants will admit to Prism Clinical Research one-time for 2 overnights

    Clinic Visits

    • There are up to 13 follow-up clinical visits

     

    Compensation for participation time:   Up to $1,860                           


    For information regarding this study contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1700: Healthy Male and Female Participants

    Research Purpose: Study 1700 is designed to evaluate the absorption/elimination rate and safety/tolerability of an investigational drug being developed for the treatment of malignant diseases.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant or breastfeeding are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    Between 18-32 kg/m²

    Tobacco/Nicotine Use

    Must be non-smoking

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements.  (Exception:  Women can be using prescribed, hormonal birth control)

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3.5 weeks.

    Inpatient Stay

    • Participants will be confined at Prism Clinical Research two separate times.
    • One clinic stay will last approximately 4 days (3 overnights)
    • The second Clinic stay will last approximately 5 days (4 overnights)

    Outpatient Visits

    • There is one outpatient visit following the final discharge from the clinic.

     

     Compensation for participation time:   Up to $1,975.00

    For information regarding this study contact Andy at 651.724.8399 or andyh@prismresearchinc.com

  • Study 1321: Healthy Male and Female Volunteers

    Study 1321: Healthy Participants

    Research Purpose:  Study 1321 is designed to evaluate an investigational drug being developed for the treatment of certain inflammatory disorders. The purpose of the study is to evaluate the absorption/elimination rate and safety/tolerability of the study drug.  

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Age 18-55 years
    • Body Mass Index (BMI) between 18-32 kg/m²
    • Must be healthy; not being evaluated or treated for any medical conditions.
    • Cannot take medications on a regular basis (Exception: women can be using a prescribed hormonal birth control)
    • No history of cancer (Exception: cured basal or squamous cell skin cancers)
    • No history of drug addiction or alcoholism 12 months prior to the screening appointment
    • No use of more than the equivalent of 5 cigarettes per week in the two months before the screening appointment.
    • Must be able and willing to refrain from use of tobacco or nicotine containing products one week before the study starts until the end of the study
    • Must be able and willing to eat/drink a study specific meal which includes pork, eggs, dairy, and gluten.

    Study Time Commitment: Study participation will last for approximately 3 ½ weeks.

    Inpatient stay

    Three short inpatient stays lasting approximately 72 hours (three overnights) each time. The inpatient stays will be separated by one week

    Outpatient Visit

    There will be one brief outpatient visit following the final inpatient stay.

    Compensation: up to $2550 for participation time 

    For information contact Dayna 651-724-5047 or email: daynas@prismresearchinc.com

Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel